Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
ompenaclid (RGX-202)
i
Other names:
RGX-202, RGX202, RGX 202, RGX-202-01
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(5)
News
Trials
Company:
EMD Serono, Inspirna
Drug class:
SLC6A8 inhibitor
‹
›
Associations
(5)
News
Trials
VERI cancer hierarchy
Reset Filters
KRAS mutation
Colorectal Cancer
KRAS mutation
Colorectal Cancer
RGX-202
Sensitive: C3 – Early Trials
RGX-202
Sensitive
:
C3
RGX-202
Sensitive: C3 – Early Trials
RGX-202
Sensitive
:
C3
KRAS G12V
Colorectal Cancer
KRAS G12V
Colorectal Cancer
RGX-202
Sensitive: C3 – Early Trials
RGX-202
Sensitive
:
C3
RGX-202
Sensitive: C3 – Early Trials
RGX-202
Sensitive
:
C3
KRAS G13D
Colorectal Cancer
KRAS G13D
Colorectal Cancer
RGX-202
Sensitive: C3 – Early Trials
RGX-202
Sensitive
:
C3
RGX-202
Sensitive: C3 – Early Trials
RGX-202
Sensitive
:
C3
KRAS mutation
Colorectal Cancer
KRAS mutation
Colorectal Cancer
bevacizumab + RGX-202
Sensitive: C3 – Early Trials
bevacizumab + RGX-202
Sensitive
:
C3
bevacizumab + RGX-202
Sensitive: C3 – Early Trials
bevacizumab + RGX-202
Sensitive
:
C3
KRAS mutation
Colorectal Cancer
KRAS mutation
Colorectal Cancer
bevacizumab + RGX-202
Sensitive: C3 – Early Trials
bevacizumab + RGX-202
Sensitive
:
C3
bevacizumab + RGX-202
Sensitive: C3 – Early Trials
bevacizumab + RGX-202
Sensitive
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login